| Penulis/Author |
VINNY ANISYA LARASATI (1); GREGORIUS VIKTOR LEMBANG (2); Yudy Tjahjono (3); drh. Sugi Winarsih, MPA (4); Prof. drg. Ika Dewi Ana, M.Kes., Ph.D. (5); Dr. med. vet. drh. Hevi Wihadmadyatami, M.Sc. (6); Prof. drh. Dwi Liliek Kusindarta, MP., Ph.D. (7) |
| Abstrak/Abstract |
Mesenchymal stem cells (MSCs) and conditioned medium (CM) derived from human
umbilical blood cord stem cells (HUBSC) are now being extensively utilized. Human umbilical vein
endothelial cells (HUVECs) have the same ability as HUBSC as an option for autologous therapy.
In addition, cell therapy using HUVECs may produce protective signals for cerebral vessels and
promote neuronal survival after hypoxic–ischemic damage. HUVECs have the same anatomical
and physiological structure as bovine umbilical vein endothelial cells (BUVECs). In this study,
we aim to determine the ability of BUVEC-CM to reduce inflammation and apoptosis on in vitro
neurodegeneration models (PC12 and SH-SY5Y cell lines). BUVEC-CM obtained from the third
and fourth passages were analyzed using liquid chromatography–mass spectrometry (LC-MS) and
high-resolution mass spectrometry (HR-MS), while the other part was used as a treatment for in vitro
model neurodegeneration. The PC12 and SH-SY5Y cell lines were cultured and grouped into seven
different treatments, including untreated cells. As the treatment group, cells were given TMT 10 µM
in the presence of different doses of CM (25%, 50%, 75%, and 100%); as a control comparison of recent
therapy, donepezil was used. In addition, cells with the administration of TMT 10 µM were run as
a positive control. Cell viability assay (CCK-8) and enzyme-linked immunosorbent assay (ELISA)
were performed to identify the viability and expression of interleukin-1β (IL-1β), caspase-3, and
caspase-9 for both PC12 and SH-SY5Y cells. The results showed that BUVEC-CM could significantly
reduce IL-1β expression and downregulate caspase-3 and caspase-9, as well as when compared to the
donepezil group. Taken together, these results indicate that BUVEC-CM can be used as a potential
candidate for neuroprotective agents by reducing the activity of IL-1β and the expression of caspase-9
and caspase-3 in PC12 and SH-SY5Y cells induced by TMT. However, further research still needs to
be conducted. |
